Figure 3.
Antitumor efficacy in vivo. (A) A549 (CD40−) and (B) EJ (CD40+) tumors were inoculated subcutaneously in the right flank of immunodeficient nude mice. Virus was injected intravenously once (as indicated with an arrow) at 1×1010 VP/mouse (n = 7 mice per group). Tumor growth was monitored after every other day. Tumor growth is expressed as percentage increase from first day of virus injection. **p < 0.01. Ad3-hTERT-CMV-hCD40L induces DC maturation: A549 tumors were injected subcutaneously in immunodeficient SCID mice (n = 5 mice per group). Virus at 1×108 VP and 1×106 DCs were injected intratumorally three times, alternatively. Proportion of dendritic cells expressing (C) CD83 (D) CD80 and (E) CD86 markers on the surface were analyzed from tumors samples by FACS. Data presented as mean ± SEM.*p ≤ 0.5, **p ≤ 0.01.